Nymox Pharmaceutical Stock Resumes Trading on OTCQB
Ticker: NYMXF · Form: 6-K · Filed: Dec 17, 2024 · CIK: 1018735
| Field | Detail |
|---|---|
| Company | Nymox Pharmaceutical CORP (NYMXF) |
| Form Type | 6-K |
| Filed Date | Dec 17, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: trading-resumption, otcqb
Related Tickers: NYMXF
TL;DR
NYMXF is back on the OTCQB, trading resumes!
AI Summary
Nymox Pharmaceutical Corporation announced on December 17, 2024, that its common stock has resumed trading on the OTCQB Venture Market under the symbol NYMXF. This follows a period where trading was likely halted or suspended.
Why It Matters
The resumption of trading indicates that the company has likely resolved issues that led to a trading halt, potentially restoring investor confidence and liquidity.
Risk Assessment
Risk Level: medium — Resumption of trading can be positive, but the reasons for any prior halt and the company's financial health remain key considerations.
Key Players & Entities
- Nymox Pharmaceutical Corporation (company) — Registrant
- NYMXF (company) — Trading Symbol
- December 17, 2024 (date) — Announcement Date
FAQ
What is the trading symbol for Nymox Pharmaceutical Corporation's common stock?
The trading symbol is NYMXF.
On which market has Nymox Pharmaceutical Corporation's common stock resumed trading?
The common stock has resumed trading on the Over the Counter QB (OTCQB) Venture Market.
When was the announcement made regarding the resumption of trading?
The announcement was made on December 17, 2024.
What form is this report filed under?
This report is filed under Form 6-K.
Is this report considered a Form 20-F or Form 40-F filing?
The registrant indicates it files annual reports under cover of Form 20-F.
Filing Stats: 244 words · 1 min read · ~1 pages · Grade level 13.4 · Accepted 2024-12-17 15:00:12
Filing Documents
- nymox_6k.htm (6-K) — 10KB
- nymox_ex991.htm (EX-99.1) — 7KB
- nymox_ex991img1.jpg (GRAPHIC) — 4KB
- nymox_ex991img2.jpg (GRAPHIC) — 4KB
- 0001640334-24-001904.txt ( ) — 30KB
From the Filing
nymox_6k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December, 2024 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant's name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F. Form 20-F Form 40-F Listing on Over the Counter QB Venture Market On December 17, 2024, Nymox Pharmaceutical Corporation (the "Company") issued a press release announcing that the Company's Common Stock has resumed trading under the symbol NYMXF on the Over the Counter QB (OTCQB) Venture Market. This press release is furnished as Exhibit 99.1 to this report on Form 6-K and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. EXHIBIT INDEX Exhibit No. Description 99.1 Press Release of Nymox Pharmaceutical Corporation, dated December 17, 2024 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 17, 2024 NYMOX PHARMACEUTICAL CORPORATION By: /s/ Paul Averback Name: Paul Averback Title: President and Chief Executive Officer 3